Results 201 to 210 of about 123,214 (256)

Protein biomarkers associated with left bundle branch block in patients with heart failure and reduced ejection fraction. [PDF]

ESC Heart Fail
Ljung K, Vestman C, Reistam U, Braunschweig F, Zhao A, Lund LH, Lang C, Voors A, Rullman E, Savarese G, Ståhlberg M.   +10 more
europepmc   +1 more source

The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study. [PDF]

Am J Cardiol
Sideris K, Bunsawat K, Brinker L, Braun E, Iacovelli J, Chen A, Simmons JM, Zhao J, Carter S, Tseliou E, Kyriakopoulos CP, Hanff TC, Florido R, Brann AM, Fang JC, Greene T, Wray DW, Stehlik J.   +17 more
europepmc   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Machine learning model for predicting improvement in left ventricular systolic function in patients with heart failure and reduced ejection fraction. [PDF]

Int J Cardiol Heart Vasc
Sepehrvand N, Gilbert C, Chunta A, Youngson E, Ezekowitz JA, Fine NM, Howlett JG, McAlister FA, Miller RJH.   +8 more
europepmc   +1 more source

Clinical Outcomes Associated With In-Hospital Versus Delayed Outpatient Initiation of Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. [PDF]

Cureus
Oletu H, Oladimeji A, Muoghalu N, Opoku KA, Osueni A, Arifayan SO, Opara IA, Okwuokei E, Peteranaba SF.   +8 more
europepmc   +1 more source

Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management. [PDF]

Heart Fail Rev
Beavers CJ, Greene SJ.
europepmc   +1 more source

Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction. [PDF]

J Cardiovasc Dev Dis
Bajec T, Žorž N, Ugovšek S, Zemljič G, Cerar A, Frljak S, Okrajšek R, Girandon Sušanj P, Šebeštjen M, Vrtovec B, Poglajen G.   +10 more
europepmc   +1 more source

The Effect of Sacubitril/Valsartan on Mood and Cognitive Function in Patients with Heart Failure with Reduced Ejection Fraction. [PDF]

Brain Sci
Al Kindi F, Al Maskari R, Al Mahruqi F, Al Riyami A, Al Yarabi Z, Kaddoura R, Al Busaidi M, Al Adawi S.   +7 more
europepmc   +1 more source